Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States gptkb:FDA |
| gptkbp:ATCCode |
L04AX08
|
| gptkbp:brand |
Tavneos
|
| gptkbp:CASNumber |
1346624-57-6
|
| gptkbp:developer |
gptkb:ChemoCentryx
gptkb:Vifor_Pharma |
| gptkbp:hasMolecularFormula |
C33H35F4N3O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
avacopan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
C5a receptor antagonist
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache hypertension hepatic enzyme increased |
| gptkbp:usedFor |
antineutrophil cytoplasmic antibody-associated vasculitis
|
| gptkbp:bfsParent |
gptkb:ChemoCentryx
|
| gptkbp:bfsLayer |
8
|